logo

 - Applications for Indonesian physicians are now open until April 9, 2024, at 23:59.

- Presents medical affairs as a new rotation in collaboration with Daewoong Group.

- The Pharmaceutical Industry Fellowship Program provides physicians with the opportunity to experience the various stages of the drug development process.

HanAll Biopharma Co., Ltd. (KRX: 009420. KS), a global biopharmaceutical company dedicated to advancing healthcare through innovation and excellence in drug development, opens applications for its prestigious Fellowship Program. 

Tailored to offer extensive training across diverse aspects of the pharmaceutical sector, this program presents a distinctive opportunity for Indonesian physicians to immerse themselves in dynamic global environments. The application period for the program will run from March 14 to April 9, 2024.

The HanAll Pharmaceutical Industry Fellowship Program aims to cultivate well-rounded physicians by offering rotations in four key areas of drug development: Clinical and Pre-clinical, Operations and Regulatory Affairs, Medical Affairs, and Business Development.

This year, in collaboration with Daewoong Group, the program introduces medical affairs as a new rotation. All participants in this program will operate under a hybrid model, spending approximately six months at the Jakarta office and the remainder working from home.

Selected participants will play a crucial role in providing insights for pre-clinical and translational work, contributing to clinical development plans, fostering relationships with scientific experts including Key Opinion Leaders, and tracking scientific developments in relevant therapeutic areas such as neurology, oncology, immunology and ophthalmology.

Interested candidates must hold an MD degree from Indonesia and demonstrate strong written and oral English communication skills to apply to this program. A keen interest in drug development, including preclinical and clinical phases, is essential, along with a curiosity for learning from different cultures. While experience in immunology, neurology, ophthalmology, or oncology is preferred, it is not mandatory. Candidates must also commit to reside in Indonesia throughout the two-year duration of the fellowship program.

Medical doctors with various competencies, including executive communication, problem-solving, and cross-cultural awareness, are encouraged to apply. Prospective fellows should exhibit proactive, dynamic personalities while also being team players, demonstrating agility and resilience in their approach.

“This program provides an eye-opening experience, introducing me to innovative career paths beyond traditional medical practice that I had never considered before. As a medical doctor, this fellowship has not only provided me with invaluable insights and knowledge not covered in medical school but also offered me international exposure through mentorship, broadening my perspective on the global healthcare landscape and the diverse opportunities within the sector,” commented Dr. Soraya Arifa, a participant in the program in 2022.

To apply, applicants are required to fill out the application form on the VIVIDAPP website, which is accessible by clicking on the banner on HanAll’s official website. The application form requires attaching a CV, an introduction video, and transcripts. Successful applicants will benefit from a hybrid work environment, annual paid leave, severance pay, experienced mentorship, and comprehensive employee benefits, including insurance.

About HanAll Biopharma

HanAll Biopharma (KRX: 009420.KS) is a global biopharmaceutical company with a presence in Korea, the USA, Japan, and Indonesia with a mission of making meaningful contributions to patients' lives by introducing innovative, impactful medicines to address severe unmet medical needs. HanAll has been operating a portfolio of pharmaceutical products in the areas of endocrine, circulatory, and urologic diseases for 51 years.

HanAll has also expanded its focus to immunology, oncology, neurology, and ophthalmology to discover and develop innovative medicines for patients with diseases for which there are no effective treatments. Its lead pipeline asset, HL161 (INN: batoclimab), an anti-FcRn antibody, is being developed in Phase 3 and Phase 2 trials across the world for the treatment of autoimmune diseases including myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP), and Graves’ disease (GD). Another main asset, HL036 (INN: tanfanercept), a TNF inhibitor protein, is being evaluated in Phase 3 clinical studies in the US and China for the treatment of dry eye disease. For further information, visit our website and connect with us on LinkedIn. For any media inquiries, please contact HanAll PR/IR (pr@hanall.com, ir@hanall.com).

Disclaimer Statement 

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements." These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "intends," "may," "will," or "should," and include statements HANALL (the company, we) makes concerning its 2024 business and financial outlook and related plans; the therapeutic potential of its product candidates; the intended results of its strategy and the company, and its collaboration partners', advancement of, and anticipated clinical development, data readouts and regulatory milestones and plans, including the timing of planned clinical trials and expected data readouts; the design of future clinical trials and the timing and outcome of regulatory filings and regulatory approvals. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The company's actual results may differ materially from those predicted by the forward-looking statements. These may include various significant factors, such as our expectations regarding the inherent uncertainties associated with competitive developments, preclinical and clinical trial and product development activities, and regulatory approval requirements. In addition, performance may be affected by our reliance on collaborations with third parties, estimating the commercial potential of our product candidates, our ability to obtain and maintain protection of intellectual property of technologies and drugs, our limited operating history, and our ability to obtain additional funding for operations and to complete the development and commercialization of product candidates. A further list and description of these risks, uncertainties, and other risks can be found in Korea Stock Exchange (KRX) filings and reports, including in our most recent annual report as well as subsequent filings and reports filed by the company with the KRX. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. We undertake no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by Korean law and regulations.